NEW YORK, Dec. 15 (GenomeWeb News) - Qiagen said today that it has licensed from Novartis a novel algorithm for the selection of siRNAs for RNA interference applications.
Under the terms of the deal, Qiagen made an undisclosed payment to Novartis for the worldwide use of the algorithm. Additional terms were not given.
Since acquiring Xeragon in 2002, Qiagen has introduced a number of RNAi products, including custom siRNA duplexes. Qiagen also signed a deal in August to provide Novartis with a genome-wide library of siRNAs for dr4ug discovery.